![Astrid Borkowski](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Astrid Borkowski currently works at HilleVax, Inc., as Chief Medical Officer from 2021.
Dr. Borkowski also formerly worked at Novartis Vaccines & Diagnostics, Inc., as Chief Medical Officer-European Region and Takeda Pharmaceuticals International, Inc., as Vice President & Head-Clinical Development.
Dr. Borkowski received her doctorate degree from Humboldt-Universität zu Berlin.
| Sociétés | Poste | Début |
|---|---|---|
| HILLEVAX, INC. | Directeur Technique/Scientifique/R&D | 01/03/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | - |
Takeda Pharmaceuticals International, Inc.
 Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting for pharmaceutical businesses | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Humboldt-Universität zu Berlin
 Humboldt-Universität zu Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting for pharmaceutical businesses | Commercial Services |
HilleVax, Inc.
 HilleVax, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in the development and commercialization of novel vaccine candidates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
